Introduction#
The term “iPS cells” is being heard more and more often in the news.
iPS cells are cells made by “” our own body cells back into a state in which they can change into many kinds of cells.
In the future they are expected to be used in “” to restore the function of tissues and organs lost to disease or injury.
On the other hand, we are not yet at the stage where “any organ can be made with iPS cells” or “they are already used as a standard treatment.”
Right now, they are at the stage of moving from basic research through clinical studies and trials into actual medical care for a limited number of diseases.
This article explains, as plainly as possible, the mechanism of iPS cells, the research, and their current clinical applications.
What are iPS cells?#
iPS cells take their name from the initials of “induced pluripotent stem cells.”
By making specific factors act on “somatic cells” such as human skin or blood, the cells are reprogrammed into cells with “pluripotency”—the ability to change into many kinds of cells such as cells, cardiomyocytes, retinal cells, hepatocytes, and pancreatic cells.
iPS cells also have the property that they can be multiplied by culturing.
What is “reprogramming”?#
A skin cell basically works as a skin cell.
This is not because the genetic information inside the cell has been lost. It is because the state of “which genes the cell uses” has changed.
In iPS cells, this state is artificially reset, returning the cell to a state in which it can differentiate into many kinds of cells.
This process is called “reprogramming (initialization).”
How are iPS cells made?#
The work that made iPS-cell research known worldwide is the research of Professor Shinya Yamanaka and colleagues at Kyoto University.
In 2006 they succeeded in making iPS cells from mouse somatic cells, and in 2007 it was reported that they had made iPS cells from human somatic cells.
Playing a key role in that process were the so-called “Yamanaka factors.”
The four representative factors are Oct3/4, Sox2, Klf4, and c-Myc.
Introducing these factors into somatic cells greatly changes the cells' state, reprogramming them into cells with pluripotency.
Today the original method has been improved, and various iPS-cell production technologies are being studied to raise safety—for example, methods that do not integrate genes into the cells' .
The key strength of iPS cells: cells can be “turned back”#
Normally in our bodies, a fertilized egg → differentiates into many cell types → skin, nerves, heart muscle, and so on—the cell's identity is decided in this direction.
Returning a cell that has already become a skin cell to a state able to become many kinds of cells was long considered extremely difficult. iPS cells overturned that assumption.
In other words, it is a technology that “returns an already-differentiated cell to a pluripotent state.”
This discovery opened new paths not only for regenerative medicine but also for studying diseases and developing new drugs.
What are iPS cells used for?#
The uses of iPS cells are easiest to understand in three broad groups.
1. Regenerative medicine: make the target cell from iPS cells and transplant it into the patient. For example, iPS cells → cardiomyocytes → heart treatment, or iPS cells → nerve cells → treatment of neurological disease—such applications are being studied.
2. Studying disease causes: making iPS cells from a patient's cells and then producing disease-related cells lets researchers study disease mechanisms. For example, making iPS cells from the cells of a patient with a neurological disease: patient-derived iPS cells → differentiate into nerve cells → study what is happening in the diseased cells. This may let researchers examine in the laboratory cells that were previously difficult to study directly from patients.
3. Developing new drugs: research is also underway in which drugs are applied to diseased cells made from iPS cells to ask “does this drug work?” “at what concentration is it effective?” and “do side effects occur?” In other words, iPS cells matter not only for treatment itself but also as a research tool for drug development.
Have treatments using iPS cells already begun?#
Yes. But this point is very important: “research on iPS cells is progressing” is not the same as “treatments using iPS cells are generally available.”
In March 2026, two regenerative medical products using iPS cells received conditional, time-limited in Japan: ReHeart (an iPS-derived cardiomyocyte sheet for severe ) and Amchepry (iPS-derived dopaminergic neural progenitor cells for ).
This marks an important stage in which iPS-based treatment is moving from “technology that stayed in the lab” toward actual medical care.
Both approvals, however, are conditional and time-limited, so effectiveness must continue to be confirmed after approval.
Which treatments use them?#
Parkinson's disease: in Parkinson's disease, the loss of dopamine-producing nerve cells in the contributes to motor symptoms.
Amchepry is a product that transplants dopamine neural progenitor cells made from iPS cells into the patient's brain. The transplanted cells are expected to differentiate and mature into dopamine-producing neurons, restoring dopaminergic function and improving motor symptoms.
In the clinical trial, seven patients received transplants and six underwent efficacy evaluation. According to Ministry of Health, Labour and Welfare materials, confirmed of the transplanted cells, and four of the six patients were judged to show improvement in motor-symptom measures. Note, however, that the trial involved a limited number of cases and that efficacy and safety must continue to be verified.
Severe heart failure: another treatment uses cardiomyocytes made from iPS cells. “ReHeart” is a product of human iPS-derived cardiomyocytes formed into sheets. For patients with severe heart failure, the is applied to the surface of the heart with the aim of improving cardiac function. It received conditional, time-limited approval in March 2026.
Research expected ahead#
Research and clinical trials targeting many diseases continue for iPS cells—for example, retinal disease, Parkinson's disease, cardiac disease, , type 1 , , and heart failure.
According to information compiled by the Kyoto University Research Foundation as of May 2026, multiple clinical studies and trials using iPS cell stocks are underway.
However, “research is underway” does not mean “efficacy is established.” Many studies and trials are still in the process of confirming safety and effectiveness.
Challenges remain for iPS cells#
iPS cells hold great promise, but challenges remain.
1. Tumor risk: because iPS cells have high proliferative capacity, any cells that fail to fully become the intended cell could lead to tumor formation. It is therefore essential to produce the target cells accurately, remove unwanted cells, and manage product quality strictly.
2. Difficulty keeping cell quality uniform: with therapies using living cells, it is hard to make products as completely uniform as conventional drugs. The Ministry of Health, Labour and Welfare also notes that because regenerative medical products use human cells, quality may be uneven reflecting individual differences, and that evaluating efficacy remains a challenge.
3. Immune reactions: when cells made from another person's iPS cells are transplanted, the patient's immune system may recognize them as foreign. Research is underway on cell selection and to address this.
“iPS cells can cure anything” is a misconception#
iPS cells have very great potential. However, we have not yet reached the stage where “using iPS cells can restore any lost organ.”
In actual medicine, the path runs: basic research (in vitro) → verification through animal studies (in vivo) → and trials → evaluation of safety and efficacy → regulatory approval → introduction into real medical care.
As of 2026, regenerative medical products using iPS cells have begun to be approved in Japan, but the target diseases and eligible patients are limited.
Summary#
iPS cells are induced pluripotent stem cells made by reprogramming body cells back to a state able to differentiate into many cell types. Their potential spans regenerative medicine, understanding disease causes, new drug development, and drug-discovery research.
And today they are moving step by step from the research stage to clinical application: in 2026, the iPS-derived regenerative medical products “Amchepry” and “ReHeart” received conditional, time-limited approval in Japan.
Still, medicine using iPS cells is developing.
“A technology with great potential” and “a technology proven able to treat every disease” are different things. As research confirming safety and efficacy accumulates, regenerative medicine using iPS cells is expected to expand further.
Going deeper#
Once the basics click, the next question is whether a given is already an approved treatment or still a research subject — the same word can mean very different things.
Reading the and Safety categories next, and checking unfamiliar terms in the glossary, will sharpen how you read future material.
Common questions#
Q. How are iPS cells made?
A. By introducing specific factors into skin or blood cells to return them to a pluripotent state — a process that takes time and quality control.
Q. Are they already used in treatment?
A. Clinical research is advancing for and spinal cord, but broad clinical use isn't here yet — distinguish research from approval.
Q. Can they be made from my own cells?
A. In principle yes, but current research mostly uses donor cell banks; making them from your own cells raises cost and time issues.